sunovion  wikipedia sunovion from wikipedia the free encyclopedia jump to navigation search sunovion pharmaceuticals inc type subsidiary industry pharmaceuticals founded  headquarters marlborough massachusetts united states key people nobuhiko tamura chairman and ceo products latuda aptiom brovana lunesta xopenex omnaris alvesco zetonna parent dainippon sumitomo pharma website httpwwwsunovioncom sunovion pharmaceuticals inc former nasdaq sepr known until october   as sepracor inc prior to its acquisition by dainippon sumitomo pharma of japan is a pharmaceutical company founded in  by timothy j barberich steve matson and bob bratzler it was originally located in princeton new jersey and then relocated to marlborough massachusetts in addition to its headquarters location in marlborough massachusetts sunovion has locations in london england mississauga ontario canada and fort lee new jersey contents  company history  acquisition by dainippon sumitomo  beneficiaries partners and subsidiaries  eslicarbazepine acetate  omnaris and alvesco  references  external links company historyedit the companys initial focus was on the development of single isomers and active metabolites this concept allowed barberich and doug reedich to generate a patent estate that served the company well for many years therapeutically sepracors products were focused on the treatment of central nervous system and respiratory disorders under the direction of gunnar aberg and john mccullough the primary source of its revenue was the approximately  million annually from its xopenex franchise of drugs launched under the marketing leadership of john simon with the direct involvement of medical communications under dean handley it is available as a multidose inhaler mdi or nebulized udv form the insomnia drug lunesta eszopiclone was discovered by tom jerussi approved by the us food and drug administration fda in december  and launched in april  under the marketing leadership of tim healy on february   sepracor filed a new drug application for brovana patented by gunnar aberg and john morley also launched under john simon to treat chronic obstructive pulmonary disease all of the launch drugs were manufactured under the leadership of walter piskorskicitation needed in september  the company announced it would acquire cynapsus therapeutics for approximately  million specifically expanding sunovians central nervous system drug portfolio through the deal sunovion would acquire cynapsus’ phase iii parkinson’s disease candidate drug apl acquisition by dainippon sumitomoedit on september   shares of sepracor were halted on the nasdaq due to pending news of a takeover bid by japanese drugmaker dainippon sumitomo according to the associated press dainippon planned to offer  billion for sepracor a nearly  premium over the stocks closing price on september  aside from acquiring such drugs as lunesta and xopenex analysts said the acquisition would give dainippon access to sepracors sales force of roughly  which would open an avenue for the japanese company to market its drugs in the united states sepracor was set to face stiff generic competition from its expiring patents xopenex in  and lunesta in  and had failed to discover any viable drugs in nearly  years a formal announcement of the acquisition was made on october   which stated that sunovion would be an indirect wholly owned subsidiary of dainippon sumitomo pharma co ltd beneficiaries partners and subsidiariesedit eslicarbazepine acetateedit in  bial agreed with sepracor that its antiepileptic eslicarbazepine acetate trade name aptiom would be produced in sepracors facilities and supervised by bial omnaris and alvescoedit the company acquired omnaris and alvesco for m upfront and an addition m in potential milestones alvesco revenues for q were  million because returns from the stocking in q exceeded the demand in q the company disclosed a  forecast of –m for omnaris and –m for alvesco yielding a combined total of mm in year  of a launch however revenues continue to be dismal prompting criticisms and concerns over the purchase price relative to minuscule income referencesedit  a b company press release  sepr profile for sepracor inc  yahoo finance  sunovion to acquire cynapsus for m  gen news highlights  gen   httpsfinanceyahoocomnewsdainipponofjapanacquiresapfhtmlxsectopstoriesposassetccode  tse suspends trade in dainippon sumitomo pharma  september  – via reuters   drugmaker sepracor accepts b buyout offer from japans dainippon  xconomy  september    aol finance news  latest business headlines from aol   bial  caring for your health  external linksedit sunovion pharmaceuticals inc retrieved from httpsenwikipediaorgwindexphptitlesunovionoldid categories companies formerly listed on nasdaqbiotechnology companies of the united statescompanies based in middlesex county massachusettsmarlborough massachusettscompanies established in hidden categories all articles with unsourced statementsarticles with unsourced statements from may  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sunovion  wikipedia sunovion from wikipedia the free encyclopedia jump to navigation search sunovion pharmaceuticals inc type subsidiary industry pharmaceuticals founded  headquarters marlborough massachusetts united states key people nobuhiko tamura chairman and ceo products latuda aptiom brovana lunesta xopenex omnaris alvesco zetonna parent dainippon sumitomo pharma website httpwwwsunovioncom sunovion pharmaceuticals inc former nasdaq sepr known until october   as sepracor inc prior to its acquisition by dainippon sumitomo pharma of japan is a pharmaceutical company founded in  by timothy j barberich steve matson and bob bratzler it was originally located in princeton new jersey and then relocated to marlborough massachusetts in addition to its headquarters location in marlborough massachusetts sunovion has locations in london england mississauga ontario canada and fort lee new jersey contents  company history  acquisition by dainippon sumitomo  beneficiaries partners and subsidiaries  eslicarbazepine acetate  omnaris and alvesco  references  external links company historyedit the companys initial focus was on the development of single isomers and active metabolites this concept allowed barberich and doug reedich to generate a patent estate that served the company well for many years therapeutically sepracors products were focused on the treatment of central nervous system and respiratory disorders under the direction of gunnar aberg and john mccullough the primary source of its revenue was the approximately  million annually from its xopenex franchise of drugs launched under the marketing leadership of john simon with the direct involvement of medical communications under dean handley it is available as a multidose inhaler mdi or nebulized udv form the insomnia drug lunesta eszopiclone was discovered by tom jerussi approved by the us food and drug administration fda in december  and launched in april  under the marketing leadership of tim healy on february   sepracor filed a new drug application for brovana patented by gunnar aberg and john morley also launched under john simon to treat chronic obstructive pulmonary disease all of the launch drugs were manufactured under the leadership of walter piskorskicitation needed in september  the company announced it would acquire cynapsus therapeutics for approximately  million specifically expanding sunovians central nervous system drug portfolio through the deal sunovion would acquire cynapsus’ phase iii parkinson’s disease candidate drug apl acquisition by dainippon sumitomoedit on september   shares of sepracor were halted on the nasdaq due to pending news of a takeover bid by japanese drugmaker dainippon sumitomo according to the associated press dainippon planned to offer  billion for sepracor a nearly  premium over the stocks closing price on september  aside from acquiring such drugs as lunesta and xopenex analysts said the acquisition would give dainippon access to sepracors sales force of roughly  which would open an avenue for the japanese company to market its drugs in the united states sepracor was set to face stiff generic competition from its expiring patents xopenex in  and lunesta in  and had failed to discover any viable drugs in nearly  years a formal announcement of the acquisition was made on october   which stated that sunovion would be an indirect wholly owned subsidiary of dainippon sumitomo pharma co ltd beneficiaries partners and subsidiariesedit eslicarbazepine acetateedit in  bial agreed with sepracor that its antiepileptic eslicarbazepine acetate trade name aptiom would be produced in sepracors facilities and supervised by bial omnaris and alvescoedit the company acquired omnaris and alvesco for m upfront and an addition m in potential milestones alvesco revenues for q were  million because returns from the stocking in q exceeded the demand in q the company disclosed a  forecast of –m for omnaris and –m for alvesco yielding a combined total of mm in year  of a launch however revenues continue to be dismal prompting criticisms and concerns over the purchase price relative to minuscule income referencesedit  a b company press release  sepr profile for sepracor inc  yahoo finance  sunovion to acquire cynapsus for m  gen news highlights  gen   httpsfinanceyahoocomnewsdainipponofjapanacquiresapfhtmlxsectopstoriesposassetccode  tse suspends trade in dainippon sumitomo pharma  september  – via reuters   drugmaker sepracor accepts b buyout offer from japans dainippon  xconomy  september    aol finance news  latest business headlines from aol   bial  caring for your health  external linksedit sunovion pharmaceuticals inc retrieved from httpsenwikipediaorgwindexphptitlesunovionoldid categories companies formerly listed on nasdaqbiotechnology companies of the united statescompanies based in middlesex county massachusettsmarlborough massachusettscompanies established in hidden categories all articles with unsourced statementsarticles with unsourced statements from may  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sunovion pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report sunovion pharmaceuticals inc  product pipeline review   published by global markets direct product code  published february   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license sunovion pharmaceuticals inc  product pipeline review   published february   content info  pages description summary global markets directs sunovion pharmaceuticals inc  product pipeline review   provides an overview of the sunovion pharmaceuticals incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by sunovion pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of sunovion pharmaceuticals inc the report provides overview of sunovion pharmaceuticals inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses sunovion pharmaceuticals incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features sunovion pharmaceuticals incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate sunovion pharmaceuticals incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for sunovion pharmaceuticals inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding sunovion pharmaceuticals incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures sunovion pharmaceuticals inc snapshot sunovion pharmaceuticals inc overview key information key facts sunovion pharmaceuticals inc  research and development overview key therapeutic areas sunovion pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities sunovion pharmaceuticals inc  pipeline products glance sunovion pharmaceuticals inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities sunovion pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities sunovion pharmaceuticals inc  early stage pipeline products indcta filed productscombination treatment modalities preclinical productscombination treatment modalities discovery productscombination treatment modalities sunovion pharmaceuticals inc  drug profiles eslicarbazepine acetate product description mechanism of action rd progress dasotraline product description mechanism of action rd progress glycopyrrolate product description mechanism of action rd progress dsp product description mechanism of action rd progress dsp product description mechanism of action rd progress sep product description mechanism of action rd progress sep product description mechanism of action rd progress sep product description mechanism of action rd progress small molecule  for neuropsychiatric disorders product description mechanism of action rd progress small molecule for neuropsychiatric disorders product description mechanism of action rd progress small molecule to inhibit damino acid oxidase for neuropathic pain inflammatory pain and memory impairment product description mechanism of action rd progress ep product description mechanism of action rd progress small molecules for central nervous system disorders product description mechanism of action rd progress small molecules to modulate gpcr and ion channel for psychiatric disorders product description mechanism of action rd progress sunovion pharmaceuticals inc  pipeline analysis sunovion pharmaceuticals inc  pipeline products by target sunovion pharmaceuticals inc  pipeline products by route of administration sunovion pharmaceuticals inc  pipeline products by molecule type sunovion pharmaceuticals inc  pipeline products by mechanism of action sunovion pharmaceuticals inc  recent pipeline updates sunovion pharmaceuticals inc  dormant projects sunovion pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles dasotraline dsp dsp sep tecastemizole sunovion pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables sunovion pharmaceuticals inc key information sunovion pharmaceuticals inc key facts sunovion pharmaceuticals inc  pipeline by indication  sunovion pharmaceuticals inc  pipeline by stage of development  sunovion pharmaceuticals inc  monotherapy products in pipeline  sunovion pharmaceuticals inc  partnered products in pipeline  sunovion pharmaceuticals inc  partnered products combination treatment modalities  sunovion pharmaceuticals inc  preregistration  sunovion pharmaceuticals inc  phase iii  sunovion pharmaceuticals inc  phase ii  sunovion pharmaceuticals inc  phase i  sunovion pharmaceuticals inc  indcta filed  sunovion pharmaceuticals inc  preclinical  sunovion pharmaceuticals inc  discovery  sunovion pharmaceuticals inc  pipeline by target  sunovion pharmaceuticals inc  pipeline by route of administration  sunovion pharmaceuticals inc  pipeline by molecule type  sunovion pharmaceuticals inc  pipeline products by mechanism of action  sunovion pharmaceuticals inc  recent pipeline updates  sunovion pharmaceuticals inc  dormant developmental projects sunovion pharmaceuticals inc  discontinued pipeline products  sunovion pharmaceuticals inc other locations sunovion pharmaceuticals inc subsidiaries list of figures sunovion pharmaceuticals inc  pipeline by top  indication  sunovion pharmaceuticals inc  pipeline by stage of development  sunovion pharmaceuticals inc  monotherapy products in pipeline  sunovion pharmaceuticals inc  partnered products in pipeline  sunovion pharmaceuticals inc  pipeline by top  target  sunovion pharmaceuticals inc  pipeline by route of administration  sunovion pharmaceuticals inc  pipeline by molecule type  sunovion pharmaceuticals inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved sunovion  wikipedia sunovion from wikipedia the free encyclopedia jump to navigation search sunovion pharmaceuticals inc type subsidiary industry pharmaceuticals founded  headquarters marlborough massachusetts united states key people nobuhiko tamura chairman and ceo products latuda aptiom brovana lunesta xopenex omnaris alvesco zetonna parent dainippon sumitomo pharma website httpwwwsunovioncom sunovion pharmaceuticals inc former nasdaq sepr known until october   as sepracor inc prior to its acquisition by dainippon sumitomo pharma of japan is a pharmaceutical company founded in  by timothy j barberich steve matson and bob bratzler it was originally located in princeton new jersey and then relocated to marlborough massachusetts in addition to its headquarters location in marlborough massachusetts sunovion has locations in london england mississauga ontario canada and fort lee new jersey contents  company history  acquisition by dainippon sumitomo  beneficiaries partners and subsidiaries  eslicarbazepine acetate  omnaris and alvesco  references  external links company historyedit the companys initial focus was on the development of single isomers and active metabolites this concept allowed barberich and doug reedich to generate a patent estate that served the company well for many years therapeutically sepracors products were focused on the treatment of central nervous system and respiratory disorders under the direction of gunnar aberg and john mccullough the primary source of its revenue was the approximately  million annually from its xopenex franchise of drugs launched under the marketing leadership of john simon with the direct involvement of medical communications under dean handley it is available as a multidose inhaler mdi or nebulized udv form the insomnia drug lunesta eszopiclone was discovered by tom jerussi approved by the us food and drug administration fda in december  and launched in april  under the marketing leadership of tim healy on february   sepracor filed a new drug application for brovana patented by gunnar aberg and john morley also launched under john simon to treat chronic obstructive pulmonary disease all of the launch drugs were manufactured under the leadership of walter piskorskicitation needed in september  the company announced it would acquire cynapsus therapeutics for approximately  million specifically expanding sunovians central nervous system drug portfolio through the deal sunovion would acquire cynapsus’ phase iii parkinson’s disease candidate drug apl acquisition by dainippon sumitomoedit on september   shares of sepracor were halted on the nasdaq due to pending news of a takeover bid by japanese drugmaker dainippon sumitomo according to the associated press dainippon planned to offer  billion for sepracor a nearly  premium over the stocks closing price on september  aside from acquiring such drugs as lunesta and xopenex analysts said the acquisition would give dainippon access to sepracors sales force of roughly  which would open an avenue for the japanese company to market its drugs in the united states sepracor was set to face stiff generic competition from its expiring patents xopenex in  and lunesta in  and had failed to discover any viable drugs in nearly  years a formal announcement of the acquisition was made on october   which stated that sunovion would be an indirect wholly owned subsidiary of dainippon sumitomo pharma co ltd beneficiaries partners and subsidiariesedit eslicarbazepine acetateedit in  bial agreed with sepracor that its antiepileptic eslicarbazepine acetate trade name aptiom would be produced in sepracors facilities and supervised by bial omnaris and alvescoedit the company acquired omnaris and alvesco for m upfront and an addition m in potential milestones alvesco revenues for q were  million because returns from the stocking in q exceeded the demand in q the company disclosed a  forecast of –m for omnaris and –m for alvesco yielding a combined total of mm in year  of a launch however revenues continue to be dismal prompting criticisms and concerns over the purchase price relative to minuscule income referencesedit  a b company press release  sepr profile for sepracor inc  yahoo finance  sunovion to acquire cynapsus for m  gen news highlights  gen   httpsfinanceyahoocomnewsdainipponofjapanacquiresapfhtmlxsectopstoriesposassetccode  tse suspends trade in dainippon sumitomo pharma  september  – via reuters   drugmaker sepracor accepts b buyout offer from japans dainippon  xconomy  september    aol finance news  latest business headlines from aol   bial  caring for your health  external linksedit sunovion pharmaceuticals inc retrieved from httpsenwikipediaorgwindexphptitlesunovionoldid categories companies formerly listed on nasdaqbiotechnology companies of the united statescompanies based in middlesex county massachusettsmarlborough massachusettscompanies established in hidden categories all articles with unsourced statementsarticles with unsourced statements from may  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sunovion  wikipedia sunovion from wikipedia the free encyclopedia jump to navigation search sunovion pharmaceuticals inc type subsidiary industry pharmaceuticals founded  headquarters marlborough massachusetts united states key people nobuhiko tamura chairman and ceo products latuda aptiom brovana lunesta xopenex omnaris alvesco zetonna parent dainippon sumitomo pharma website httpwwwsunovioncom sunovion pharmaceuticals inc former nasdaq sepr known until october   as sepracor inc prior to its acquisition by dainippon sumitomo pharma of japan is a pharmaceutical company founded in  by timothy j barberich steve matson and bob bratzler it was originally located in princeton new jersey and then relocated to marlborough massachusetts in addition to its headquarters location in marlborough massachusetts sunovion has locations in london england mississauga ontario canada and fort lee new jersey contents  company history  acquisition by dainippon sumitomo  beneficiaries partners and subsidiaries  eslicarbazepine acetate  omnaris and alvesco  references  external links company historyedit the companys initial focus was on the development of single isomers and active metabolites this concept allowed barberich and doug reedich to generate a patent estate that served the company well for many years therapeutically sepracors products were focused on the treatment of central nervous system and respiratory disorders under the direction of gunnar aberg and john mccullough the primary source of its revenue was the approximately  million annually from its xopenex franchise of drugs launched under the marketing leadership of john simon with the direct involvement of medical communications under dean handley it is available as a multidose inhaler mdi or nebulized udv form the insomnia drug lunesta eszopiclone was discovered by tom jerussi approved by the us food and drug administration fda in december  and launched in april  under the marketing leadership of tim healy on february   sepracor filed a new drug application for brovana patented by gunnar aberg and john morley also launched under john simon to treat chronic obstructive pulmonary disease all of the launch drugs were manufactured under the leadership of walter piskorskicitation needed in september  the company announced it would acquire cynapsus therapeutics for approximately  million specifically expanding sunovians central nervous system drug portfolio through the deal sunovion would acquire cynapsus’ phase iii parkinson’s disease candidate drug apl acquisition by dainippon sumitomoedit on september   shares of sepracor were halted on the nasdaq due to pending news of a takeover bid by japanese drugmaker dainippon sumitomo according to the associated press dainippon planned to offer  billion for sepracor a nearly  premium over the stocks closing price on september  aside from acquiring such drugs as lunesta and xopenex analysts said the acquisition would give dainippon access to sepracors sales force of roughly  which would open an avenue for the japanese company to market its drugs in the united states sepracor was set to face stiff generic competition from its expiring patents xopenex in  and lunesta in  and had failed to discover any viable drugs in nearly  years a formal announcement of the acquisition was made on october   which stated that sunovion would be an indirect wholly owned subsidiary of dainippon sumitomo pharma co ltd beneficiaries partners and subsidiariesedit eslicarbazepine acetateedit in  bial agreed with sepracor that its antiepileptic eslicarbazepine acetate trade name aptiom would be produced in sepracors facilities and supervised by bial omnaris and alvescoedit the company acquired omnaris and alvesco for m upfront and an addition m in potential milestones alvesco revenues for q were  million because returns from the stocking in q exceeded the demand in q the company disclosed a  forecast of –m for omnaris and –m for alvesco yielding a combined total of mm in year  of a launch however revenues continue to be dismal prompting criticisms and concerns over the purchase price relative to minuscule income referencesedit  a b company press release  sepr profile for sepracor inc  yahoo finance  sunovion to acquire cynapsus for m  gen news highlights  gen   httpsfinanceyahoocomnewsdainipponofjapanacquiresapfhtmlxsectopstoriesposassetccode  tse suspends trade in dainippon sumitomo pharma  september  – via reuters   drugmaker sepracor accepts b buyout offer from japans dainippon  xconomy  september    aol finance news  latest business headlines from aol   bial  caring for your health  external linksedit sunovion pharmaceuticals inc retrieved from httpsenwikipediaorgwindexphptitlesunovionoldid categories companies formerly listed on nasdaqbiotechnology companies of the united statescompanies based in middlesex county massachusettsmarlborough massachusettscompanies established in hidden categories all articles with unsourced statementsarticles with unsourced statements from may  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sunovion  wikipedia sunovion from wikipedia the free encyclopedia jump to navigation search sunovion pharmaceuticals inc type subsidiary industry pharmaceuticals founded  headquarters marlborough massachusetts united states key people nobuhiko tamura chairman and ceo products latuda aptiom brovana lunesta xopenex omnaris alvesco zetonna parent dainippon sumitomo pharma website httpwwwsunovioncom sunovion pharmaceuticals inc former nasdaq sepr known until october   as sepracor inc prior to its acquisition by dainippon sumitomo pharma of japan is a pharmaceutical company founded in  by timothy j barberich steve matson and bob bratzler it was originally located in princeton new jersey and then relocated to marlborough massachusetts in addition to its headquarters location in marlborough massachusetts sunovion has locations in london england mississauga ontario canada and fort lee new jersey contents  company history  acquisition by dainippon sumitomo  beneficiaries partners and subsidiaries  eslicarbazepine acetate  omnaris and alvesco  references  external links company historyedit the companys initial focus was on the development of single isomers and active metabolites this concept allowed barberich and doug reedich to generate a patent estate that served the company well for many years therapeutically sepracors products were focused on the treatment of central nervous system and respiratory disorders under the direction of gunnar aberg and john mccullough the primary source of its revenue was the approximately  million annually from its xopenex franchise of drugs launched under the marketing leadership of john simon with the direct involvement of medical communications under dean handley it is available as a multidose inhaler mdi or nebulized udv form the insomnia drug lunesta eszopiclone was discovered by tom jerussi approved by the us food and drug administration fda in december  and launched in april  under the marketing leadership of tim healy on february   sepracor filed a new drug application for brovana patented by gunnar aberg and john morley also launched under john simon to treat chronic obstructive pulmonary disease all of the launch drugs were manufactured under the leadership of walter piskorskicitation needed in september  the company announced it would acquire cynapsus therapeutics for approximately  million specifically expanding sunovians central nervous system drug portfolio through the deal sunovion would acquire cynapsus’ phase iii parkinson’s disease candidate drug apl acquisition by dainippon sumitomoedit on september   shares of sepracor were halted on the nasdaq due to pending news of a takeover bid by japanese drugmaker dainippon sumitomo according to the associated press dainippon planned to offer  billion for sepracor a nearly  premium over the stocks closing price on september  aside from acquiring such drugs as lunesta and xopenex analysts said the acquisition would give dainippon access to sepracors sales force of roughly  which would open an avenue for the japanese company to market its drugs in the united states sepracor was set to face stiff generic competition from its expiring patents xopenex in  and lunesta in  and had failed to discover any viable drugs in nearly  years a formal announcement of the acquisition was made on october   which stated that sunovion would be an indirect wholly owned subsidiary of dainippon sumitomo pharma co ltd beneficiaries partners and subsidiariesedit eslicarbazepine acetateedit in  bial agreed with sepracor that its antiepileptic eslicarbazepine acetate trade name aptiom would be produced in sepracors facilities and supervised by bial omnaris and alvescoedit the company acquired omnaris and alvesco for m upfront and an addition m in potential milestones alvesco revenues for q were  million because returns from the stocking in q exceeded the demand in q the company disclosed a  forecast of –m for omnaris and –m for alvesco yielding a combined total of mm in year  of a launch however revenues continue to be dismal prompting criticisms and concerns over the purchase price relative to minuscule income referencesedit  a b company press release  sepr profile for sepracor inc  yahoo finance  sunovion to acquire cynapsus for m  gen news highlights  gen   httpsfinanceyahoocomnewsdainipponofjapanacquiresapfhtmlxsectopstoriesposassetccode  tse suspends trade in dainippon sumitomo pharma  september  – via reuters   drugmaker sepracor accepts b buyout offer from japans dainippon  xconomy  september    aol finance news  latest business headlines from aol   bial  caring for your health  external linksedit sunovion pharmaceuticals inc retrieved from httpsenwikipediaorgwindexphptitlesunovionoldid categories companies formerly listed on nasdaqbiotechnology companies of the united statescompanies based in middlesex county massachusettsmarlborough massachusettscompanies established in hidden categories all articles with unsourced statementsarticles with unsourced statements from may  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sunovion pharmaceuticals inc private company information  bloomberg july    pm et pharmaceuticals company overview of sunovion pharmaceuticals inc snapshot people company overview sunovion pharmaceuticals inc develops and markets pharmaceutical products the company offers products for central nervous system disorders such as insomnia schizophrenia bipolar depression and epilepsy disorders attention deficit hyperactivity and bingeeating disorders and respiratory conditions including asthma allergy and chronic obstructive pulmonary disease areas sunovion pharmaceuticals inc was formerly known as sepracor inc and changed its name to sunovion pharmaceuticals inc in october  the company was founded in  and is headquartered in marlborough massachusetts as of october   sunovion pharmaceuticals inc operates as a subsidiary of dainippon sumi sunovion pharmaceuticals inc develops and markets pharmaceutical products the company offers products for central nervous system disorders such as insomnia schizophrenia bipolar depression and epilepsy disorders attention deficit hyperactivity and bingeeating disorders and respiratory conditions including asthma allergy and chronic obstructive pulmonary disease areas sunovion pharmaceuticals inc was formerly known as sepracor inc and changed its name to sunovion pharmaceuticals inc in october  the company was founded in  and is headquartered in marlborough massachusetts as of october   sunovion pharmaceuticals inc operates as a subsidiary of dainippon sumitomo pharma america holdings inc detailed description  waterford drivemarlborough ma united statesfounded in  employees phone  fax  wwwsunovioncom key executives for sunovion pharmaceuticals inc mr nobuhiko tamura chairman and chief executive officer mr stephen freeman chief financial officer and senior vice president mr robert gregorio chief administrative officer and executive vice president mr matthew d’ambrosio chief compliance  ethics officer and senior vice president dr antony loebel md chief medical officer executive vice president and head of global clinical development compensation as of fiscal year  sunovion pharmaceuticals inc key developments sunovion’s latuda® lurasidone hci receives health canada approval to treat adolescents with schizophrenia jul   sunovion pharmaceuticals inc announced that health canada approved the supplemental new drug submission snds for latuda® lurasidone hci for the management of the manifestations of schizophrenia in adolescents aged  to  years latuda is currently indicated in canada for the management of the manifestations of schizophrenia and the acute management of depressive episodes associated with bipolar i disorder in adults the approval is based on results from a randomized doubleblind placebocontrolled sixweek study in which adolescent patients with schizophrenia received fixed doses of latuda  mgday latuda  mgday or placebo at study endpoint patients treated with latuda  mgday and  mgday demonstrated statistically significant and clinically meaningful improvement in symptoms of schizophrenia compared to placebo latuda was also generally well tolerated with limited effects on weight and metabolic parameters sunovion pharmaceuticals inc announces fda acceptance for review of new drug application resubmission for suneflow glycopyrrolate for the treatment of chronic obstructive pulmonary disease jun   sunovion pharmaceuticals inc announced that the us food and drug administration fda has accepted for review the resubmission of the new drug application for suneflow® glycopyrrolate for the longterm maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis andor emphysema this resubmission is in response to the complete response letter sunovion received from the fda on may   the expected action date by the fda under the prescription drug user fee act pdufa is december   the nda for suneflow is supported by data from clinical trials in the golden glycopyrrolate for obstructive lung disease via electronic nebulizer program which demonstrated a statistically significant change from baseline in morning predose trough forced expiratory volume in one second fev versus placebo in addition to safety and tolerability in a longterm study sunovion was not required by the fda to conduct any additional clinical studies prior to nda resubmission sunovion announces utibron™ neohaler® inhalation powder data showing lung function and healthrelated quality of life improvement in patients with moderatetosevere chronic obstructive pulmonary disease may   sunovion pharmaceuticals inc announced that multiple data analyses from two phase  studies demonstrating that utibron™ neohaler® indacaterolglycopyrrolate inhalation powder improved lung function healthrelated quality of life hrql dyspnea and nighttime symptoms compared to placebo in patients with moderatetosevere chronic obstructive pulmonary disease copd were presented at the  american thoracic society international conference ats  held may   in washington dc findings from the flight and flight pivotal efficacy and safety studies as well as from the flight longterm safety study were included in nine posters for utibron neohaler presented at the meeting utibron neohaler is a twicedaily combination longacting beta agonist indacaterol and longacting muscarinic antagonist glycopyrrolate labalama for the longterm maintenance treatment of airflow obstruction in people with copd including chronic bronchitis andor emphysema utibron neohaler is not indicated to treat asthma or for the relief of sudden symptoms of copd key data presented at ats  include a pooled analysis of efficacy results from flight and flight studies which showed that utibron neohaler demonstrated significant and sustained improvement in lung function compared to placebo as measured by timeweighted mean forced expiratory volume in  second fev treatment differences between utibron neohaler and placebo ranged from  to  l on day  and from  to  l at week  all pvalues results from a pooled analysis of hrql data from flight and flight studies showed that patients treated with utibron neohaler for moderatetosevere copd had statistically and clinically significant improvements in disease specific health related quality of life as measured by the st georges respiratory questionnaire sgrq and dyspnea as measured by the transition dyspnea index tdi compared to placebo treated patients after  weeks of treatment these improvements were seen in all patients irrespective of age gender severity of disease smoking status or baseline use of drugs like corticosteroids two pooled analyses of flight and flight trials evaluated the effect of utibron neohaler on patientreported daily total copd symptoms nighttime use of rescue medication and sleep disturbance one of these presentations showed that patients treated with utibron neohaler reported significant reduction in their total nighttime copd symptoms score versus placebo over the week treatment period a separate pooled analysis showed that  weeks of treatment with utibron neohaler significantly reduced the use of rescue medications at night and significantly increased the number of nights with no awakenings compared to placebo specifically a significant reduction in the number of nighttime rescue medication puffs use treatment difference  standard error se   p   and significant increases in the percentage of nights with no awakenings treatment difference  se   p   compared to placebo were seen after  weeks of treatment similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact sunovion pharmaceuticals inc please visit wwwsunovioncom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close sunovion  sunovion – join us sunovion close video at sunovion your impact will be felt near and far you have the opportunity to be at the forefront of innovation if youre curious passionate and determined to make a difference join us build a career that helps you reach your potential while no two careers are alike there are some general similarities within your areas of specialty take a look at two typical career paths in our organization youll quickly see that the success of our employees is fueled by hard work and dedication sales managed markets keep on track and be more productive with our experiential learning programs at sunovion handson learning is an important component of our development platform our goal is to offer our employees the professional education programs they need to help them reach their potential examples include corporate leadership rotation program field to corporate rotation program global assignment program enjoy the benefits and resources you’d expect from a global organization our employees’ health and wellness are important—that’s why sunovion remains committed to providing benefits and resources that support all facets of their lives we offer a range of benefits to assist employees and their families for details about benefits in united states canada and the eu visit united states wwwsunovionus canada wwwsunovionca europe wwwsunovioneu meet our people our history find out about our milestones and successes since our inception discover more about sunovions history our people our employees strive to make a difference in people’s lives meet the people of sunovion our pipeline we are researching and developing new treatment options for serious medical conditions see what were working on sunovion  sunovion – our therapies sunovion close video making an unwavering commitment to support people with serious medical conditions our therapies our track record of discovery development and commercialization of important therapies includes brovana® arformoterol tartrate latuda® lurasidone hcl and aptiom® eslicarbazepine acetate our approved therapies also include utibron™ neohaler® indacaterol and glycopyrrolate inhalation powder seebri™ neohaler® glycopyrrolate inhalation powder arcapta® neohaler® indacaterol inhalation powder sunovion has a robust portfolio and is expanding leadership in treatments for psychiatric neurologic and respiratory conditions through our pharmaceutical research and collaborations we have had  therapies approved by the us food and drug administration fda psychiatric conditions find out what types of psychiatric conditions we’re prioritizing explore our investigations into psychiatric conditions respiratory learn how we’re focusing our respiratory efforts discover our areas of respiratory research our pipeline we are researching and developing new treatment options for serious medical conditions see what we’re working on sunovion  sunovion – central nervous system disorders – bipolar disorder sunovion close video bipolar disorder how bipolar disorder impacts peoples lives bipolar disorder a mental health condition that requires longterm treatment and is characterized by debilitating mood swings affects approximately  million adults in the united states it is among the top  leading causes of disability in the united states bipolar i disorder is characterized by at least one lifetime manic or mixed episode often individuals have one or more depressive episodes bipolar depression refers to the depressive phase of bipolar i disorder its symptoms may include depressed mood loss of interest or pleasure in activities significant weight loss insomnia fatigue feelings of worthlessness diminished ability to concentrate and recurrent thoughts of death or suicide attempt when symptomatic most individuals with bipolar disorder spend more time in the depressive phase depressive episodes associated with bipolar disorder have been shown to result in significant impairment in work family and social function and are associated with increased risk of suicide and direct and indirect healthcare costs learn how to partner with us about bipolar i disorder m adults are affected in the us at least  manic or mixed episode in a persons lifetime characterizes bipolar disorder a top  cause of disability in the united states partner with us discover the many benefits of partnering with sunovion learn how to become a partner our pipeline we are researching and developing new treatment options for serious medical conditions see what were working on psychiatric conditions find out what psychiatric conditions we’re prioritizing explore our investigations into psychiatric conditions page sources sunovion  sunovion – central nervous system disorders – bipolar disorder sunovion close video bipolar disorder how bipolar disorder impacts peoples lives bipolar disorder a mental health condition that requires longterm treatment and is characterized by debilitating mood swings affects approximately  million adults in the united states it is among the top  leading causes of disability in the united states bipolar i disorder is characterized by at least one lifetime manic or mixed episode often individuals have one or more depressive episodes bipolar depression refers to the depressive phase of bipolar i disorder its symptoms may include depressed mood loss of interest or pleasure in activities significant weight loss insomnia fatigue feelings of worthlessness diminished ability to concentrate and recurrent thoughts of death or suicide attempt when symptomatic most individuals with bipolar disorder spend more time in the depressive phase depressive episodes associated with bipolar disorder have been shown to result in significant impairment in work family and social function and are associated with increased risk of suicide and direct and indirect healthcare costs learn how to partner with us about bipolar i disorder m adults are affected in the us at least  manic or mixed episode in a persons lifetime characterizes bipolar disorder a top  cause of disability in the united states partner with us discover the many benefits of partnering with sunovion learn how to become a partner our pipeline we are researching and developing new treatment options for serious medical conditions see what were working on psychiatric conditions find out what psychiatric conditions we’re prioritizing explore our investigations into psychiatric conditions page sources sunovion  sunovion – join us sunovion close video at sunovion your impact will be felt near and far you have the opportunity to be at the forefront of innovation if youre curious passionate and determined to make a difference join us build a career that helps you reach your potential while no two careers are alike there are some general similarities within your areas of specialty take a look at two typical career paths in our organization youll quickly see that the success of our employees is fueled by hard work and dedication sales managed markets keep on track and be more productive with our experiential learning programs at sunovion handson learning is an important component of our development platform our goal is to offer our employees the professional education programs they need to help them reach their potential examples include corporate leadership rotation program field to corporate rotation program global assignment program enjoy the benefits and resources you’d expect from a global organization our employees’ health and wellness are important—that’s why sunovion remains committed to providing benefits and resources that support all facets of their lives we offer a range of benefits to assist employees and their families for details about benefits in united states canada and the eu visit united states wwwsunovionus canada wwwsunovionca europe wwwsunovioneu meet our people our history find out about our milestones and successes since our inception discover more about sunovions history our people our employees strive to make a difference in people’s lives meet the people of sunovion our pipeline we are researching and developing new treatment options for serious medical conditions see what were working on ﻿ sunovion  sunovion – home page sunovion close video lead the way to a healthier world by putting patients at the center of everything we do we are focused on developing innovative therapies and transforming the lives of people with serious medical conditions watch video helping people with serious medical conditions lead fulfilling lives building on a track record of discovery development and commercialization of important therapies we have a robust and growing portfolio of treatments to address serious psychiatric neurological and respiratory conditions explore our pipeline our therapies find out how we are addressing serious psychiatric conditions we are investigating novel treatments to psychiatric disorders that will help people with these conditions live better lives take a look at our areas of psychiatric research discover what were doing to investigate serious neurological conditions we are engaged in the quest for treatment paths that will improve the lives of millions impacted by neurologic conditions review the focus of our neurological research explore our research in serious respiratory conditions we strive to advance the science of medicine for respiratory conditions see where we are concentrating our respiratory research featured news most recent july   sunovion’s latuda® lurasidone hci receives health canada approval to treat adolescents with schizophrenia read our announcement july   sunovion expands commitment to building stronger communities through partnerships with the red sox foundation united way of tricounty and bergen volunteer center read our announcement july   sunovion enters agreement to divest asthma and allergy products to covis pharma read our announcement our people share a passion to make a difference our commitment supporting patient advocacy in our communities we partner with leading patient advocacy organizations and participate in a wide variety of events that help to raise awareness and support educational and research programs sunovion by the numbers ndfastestgrowing pharmaceutical company in the us employees worldwide employee volunteer hours in  years see how we make a difference hands on learn more about sunovion’s annual day of community service page sources sunovion  sunovion – our people page sunovion close video our people meet a compassionate team devoted to improving the lives of people compassion ethics and dedication unify sunovion employees its evident that our people are the foundation of our business meet a few members of the sunovion team who we are sunovions vision is to lead the way to a healthier world learn more about us our mission vision  values understand why were focused on helping people with serious medical conditions learn about sunovions mission vision and values our pipeline we are researching and developing new treatment options for serious medical conditions see what we’re working on sunovion  sunovion – join us sunovion close video at sunovion your impact will be felt near and far you have the opportunity to be at the forefront of innovation if youre curious passionate and determined to make a difference join us build a career that helps you reach your potential while no two careers are alike there are some general similarities within your areas of specialty take a look at two typical career paths in our organization youll quickly see that the success of our employees is fueled by hard work and dedication sales managed markets keep on track and be more productive with our experiential learning programs at sunovion handson learning is an important component of our development platform our goal is to offer our employees the professional education programs they need to help them reach their potential examples include corporate leadership rotation program field to corporate rotation program global assignment program enjoy the benefits and resources you’d expect from a global organization our employees’ health and wellness are important—that’s why sunovion remains committed to providing benefits and resources that support all facets of their lives we offer a range of benefits to assist employees and their families for details about benefits in united states canada and the eu visit united states wwwsunovionus canada wwwsunovionca europe wwwsunovioneu meet our people our history find out about our milestones and successes since our inception discover more about sunovions history our people our employees strive to make a difference in people’s lives meet the people of sunovion our pipeline we are researching and developing new treatment options for serious medical conditions see what were working on sunovion  sunovion – hands on event page sunovion close video hands on  marked the fifth year of sunovion’s annual community service program hands on since the inception of the program in  sunovion employees have volunteered more than  hours to support youth organizations and community service efforts around our headquarters located in marlborough massachusetts and its office in fort lee new jersey sunovion will continue to expand hands on through employee volunteer efforts on projects throughout the us as well as in communities where we have offices in the uk and canada event highlights  employees participated in hands on in  more than k community service hours since   community projects supported in  in our own words responsibility our employees have a collective commitment to give back make a difference together and improve lives learn more about how we care for the community community building building stronger communities where our employees live and work discover how we support our communities who we are sunovions vision is to lead the way to a healthier world learn more about us sunovion  sunovion – explore partnerships sunovion close video explore partnership opportunities collaborating to access innovation who we are sunovion is entrepreneurial with an open minded culture embracing the challenges of a fast paced environment we focus on complementing our partners with our expertise and commercial capabilities we implement partnerships that create value for patients and achieve mutual success for shareholders our therapeutic areas of interest we focus on psychiatry neurology and respiratory sunovion is currently interested in partnering with organizations in the discovery development and commercialization of novel therapies within psychiatry neurology and respiratory our commitment to innovation is highlighted by our efforts to expand in digital healthcare by investing in technologies that support the new paradigm of connected care interested in exploring partnership opportunities get in touch submit an idea to our partnering team our partners find out about some of our most successful partnerships discover more about our partners our therapies get information and resources on our therapeutic treatments see our us product portfolio our history find out about our milestones and successes since our inception discover more about sunovions history sunovion  sunovion – our people page sunovion close video our people meet a compassionate team devoted to improving the lives of people compassion ethics and dedication unify sunovion employees its evident that our people are the foundation of our business meet a few members of the sunovion team who we are sunovions vision is to lead the way to a healthier world learn more about us our mission vision  values understand why were focused on helping people with serious medical conditions learn about sunovions mission vision and values our pipeline we are researching and developing new treatment options for serious medical conditions see what we’re working on ﻿ sunovion  sunovion – home page sunovion close video lead the way to a healthier world by putting patients at the center of everything we do we are focused on developing innovative therapies and transforming the lives of people with serious medical conditions watch video helping people with serious medical conditions lead fulfilling lives building on a track record of discovery development and commercialization of important therapies we have a robust and growing portfolio of treatments to address serious psychiatric neurological and respiratory conditions explore our pipeline our therapies find out how we are addressing serious psychiatric conditions we are investigating novel treatments to psychiatric disorders that will help people with these conditions live better lives take a look at our areas of psychiatric research discover what were doing to investigate serious neurological conditions we are engaged in the quest for treatment paths that will improve the lives of millions impacted by neurologic conditions review the focus of our neurological research explore our research in serious respiratory conditions we strive to advance the science of medicine for respiratory conditions see where we are concentrating our respiratory research featured news most recent july   sunovion’s latuda® lurasidone hci receives health canada approval to treat adolescents with schizophrenia read our announcement july   sunovion expands commitment to building stronger communities through partnerships with the red sox foundation united way of tricounty and bergen volunteer center read our announcement july   sunovion enters agreement to divest asthma and allergy products to covis pharma read our announcement our people share a passion to make a difference our commitment supporting patient advocacy in our communities we partner with leading patient advocacy organizations and participate in a wide variety of events that help to raise awareness and support educational and research programs sunovion by the numbers ndfastestgrowing pharmaceutical company in the us employees worldwide employee volunteer hours in  years see how we make a difference hands on learn more about sunovion’s annual day of community service page sources sunovion  sunovion – explore partnerships sunovion close video explore partnership opportunities collaborating to access innovation who we are sunovion is entrepreneurial with an open minded culture embracing the challenges of a fast paced environment we focus on complementing our partners with our expertise and commercial capabilities we implement partnerships that create value for patients and achieve mutual success for shareholders our therapeutic areas of interest we focus on psychiatry neurology and respiratory sunovion is currently interested in partnering with organizations in the discovery development and commercialization of novel therapies within psychiatry neurology and respiratory our commitment to innovation is highlighted by our efforts to expand in digital healthcare by investing in technologies that support the new paradigm of connected care interested in exploring partnership opportunities get in touch submit an idea to our partnering team our partners find out about some of our most successful partnerships discover more about our partners our therapies get information and resources on our therapeutic treatments see our us product portfolio our history find out about our milestones and successes since our inception discover more about sunovions history sepr stock quote  sunovion pharmaceuticals inc  bloomberg markets error could not add to watchlist x  watchlist sunovion pharmaceuticals inc seprus acquired seprus was acquired by dus usd volume  before its here its on the bloomberg terminal learn more volume  current pe ratio ttm  earnings per share usd ttm  market cap usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  sunovion announces positive results from pivotal study evaluating novel drug candidate dasotraline in adults with binge eating  sunovion presents phase  data showing safety efficacy and improvement in quality of life outcomes in patients with moderateto  sunovion announces positive results from study evaluating latuda® lurasidone hcl in children and adolescents with bipolar  us fda accepts for review supplemental new drug application for aptiom® eslicarbazepine acetate for the treatment of  sunovion announces positive results from pivotal study evaluating novel drug candidate dasotraline in children with adhd  sunovion submits supplemental new drug application to fda for use of aptiom® eslicarbazepine acetate for the treatment of  sunovion announces positive topline results from study evaluating latuda® lurasidone hcl in children and adolescents with there are currently no press releases for this ticker please check back later profile sunovion pharmaceuticals inc manufactures pharmaceutical products the company develops and produces medicines for the treatment of central nervous system and respiratory ailments such as schizophrenia depression epilepsy neuropathic pain and insomnia sunovion pharmaceuticals serves customers in the united states address  waterford drivemarlborough ma united states phone  website wwwsunovioncom executives board members nobuhiko tamura chairmanceo robert gregorio exec vpcao hiroyuki baba executive vp antony loebel exec vpchief medical officer matthew dambrosio senior vpchief compliance ofcr show more sunovion  sunovion – our therapies sunovion close video making an unwavering commitment to support people with serious medical conditions our therapies our track record of discovery development and commercialization of important therapies includes brovana® arformoterol tartrate latuda® lurasidone hcl and aptiom® eslicarbazepine acetate our approved therapies also include utibron™ neohaler® indacaterol and glycopyrrolate inhalation powder seebri™ neohaler® glycopyrrolate inhalation powder arcapta® neohaler® indacaterol inhalation powder sunovion has a robust portfolio and is expanding leadership in treatments for psychiatric neurologic and respiratory conditions through our pharmaceutical research and collaborations we have had  therapies approved by the us food and drug administration fda psychiatric conditions find out what types of psychiatric conditions we’re prioritizing explore our investigations into psychiatric conditions respiratory learn how we’re focusing our respiratory efforts discover our areas of respiratory research our pipeline we are researching and developing new treatment options for serious medical conditions see what we’re working on ﻿ sunovion  sunovion – home page sunovion close video lead the way to a healthier world by putting patients at the center of everything we do we are focused on developing innovative therapies and transforming the lives of people with serious medical conditions watch video helping people with serious medical conditions lead fulfilling lives building on a track record of discovery development and commercialization of important therapies we have a robust and growing portfolio of treatments to address serious psychiatric neurological and respiratory conditions explore our pipeline our therapies find out how we are addressing serious psychiatric conditions we are investigating novel treatments to psychiatric disorders that will help people with these conditions live better lives take a look at our areas of psychiatric research discover what were doing to investigate serious neurological conditions we are engaged in the quest for treatment paths that will improve the lives of millions impacted by neurologic conditions review the focus of our neurological research explore our research in serious respiratory conditions we strive to advance the science of medicine for respiratory conditions see where we are concentrating our respiratory research featured news most recent july   sunovion’s latuda® lurasidone hci receives health canada approval to treat adolescents with schizophrenia read our announcement july   sunovion expands commitment to building stronger communities through partnerships with the red sox foundation united way of tricounty and bergen volunteer center read our announcement july   sunovion enters agreement to divest asthma and allergy products to covis pharma read our announcement our people share a passion to make a difference our commitment supporting patient advocacy in our communities we partner with leading patient advocacy organizations and participate in a wide variety of events that help to raise awareness and support educational and research programs sunovion by the numbers ndfastestgrowing pharmaceutical company in the us employees worldwide employee volunteer hours in  years see how we make a difference hands on learn more about sunovion’s annual day of community service page sources data dumps    freebase api deprecated    google developers freebase api deprecated all products sign in send feedback hey there are you maybe looking for firebase instead data dumps the freebase api will be completely shutdown on aug   this page provides access to the last available data dump read more data dumps are a downloadable version of the data in freebase they constitute a snapshot of the data stored in freebase and the schema that structures it and are provided under the same ccby license the freebasewikidata mappings are provided under the cc license freebase triples freebase deleted triples freebasewikidata mappings license citing freebase triples this dataset contains every fact currently in freebase total triples  billion updated weekly data format ntriples rdf license ccby  gb gzip gb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagedate httpwwwworgxmlschemagyearmonth  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagesource httprdffreebasecomnsgxgfm  httprdffreebasecomnsgvjzynm httprdffreebasecomnstypeobjecttype httprdffreebasecomnsmeasurementunitdatedpercentage  httprdffreebasecomnsgvjzynm httprdffreebasecomnsmeasurementunitdatedpercentagerate   httprdffreebasecomnsgvjzynm httpwwwworgrdfsyntaxnstype httprdffreebasecomnsmeasurementunitdatedpercentage  if youre writing your own code to parse the rdf dumps its often more efficient to read directly from gzip file rather than extracting the data first and then processing the uncompressed data subject predicate object  note in freebase objects have mids that look like mrkqx in rdf those mids become mrkqx likewise freebase schema like commontopic are written as commontopic the subject is the id of a freebase object it can be a freebase mid ex mrkqx for topics and cvts or a humanreadable id ex commontopic for schema the predicate is always a humanreadable id for a freebase property or a property from a standard rdf vocabulary like rdfs freebase foreign key namespaces are also used as predicates to make it easier to look up keys by namespace the object field may contain a freebase mid for an object or a humanreadable id for schema from freebase or other rdf vocabularies it may also include literal values like strings booleans and numeric values topic descriptions often contain newlines in order to make each triple fit on one line we have escaped newlines with n freebase deleted triples we also provide a dump of triples that have been deleted from freebase over time this is a onetime dump through march  in the future we might consider providing periodic updates of recently deleted triples but at the moment we have no specific timeframe for doing so and are only providing this onetime dump the dump is distributed as a targz file gb compressed gb uncompressed it contains  deleted triples in  files there is no particular meaning to the individual files it is just easier to manipulate several smaller files than one huge file thanks to chun how tan and john giannandrea for making this data release possible total triples  million updated june   data format csv license ccby  gb gzip gb uncompressed download the data format is essentially csv with one important caveat the object field may contain any characters including commas as well as any other reasonable delimiters you could think of however all the other fields are guaranteed not to contain commas so the data can still be parsed unambiguously the columns in the dataset are defined as creationtimestamp unix epoch time in milliseconds creator deletiontimestamp unix epoch time in milliseconds deletor subject mid predicate mid object midliteral languagecode csv usermwclwikipediaenusermwclwikipediaenmrtypeobjectkeywikipediaenben usermwclmusicbrainzuserturtlewaxbotmnncpzmusicrecordingartistmvbfmen usermwclimagesusergardeningbotmwmcommonimagesizemklyen usermwclmusicbrainzusermbzpipelinemergebotmfvvltypeobjecttypecommontopicen usermwclimagesusergardeningbotmxsczcommonlicensedobjectlicensemxben usercontentadministratorusergardeningbotmgkbytypeobjecttypetypecontenten usermwclimagesusergardeningbotmhcommontopicimagemcsen usermwclchefmozuserdeletebotmzcztypeobjectnamela casa rosa mexican restauranten freebasewikidata mappings the data has been created based on the wikidatadump of october   and contains only those links that have at least two common wikipedialinks and not a single disagreeing wikipedialink furthermore the lines are sorted by the number of common wikipedialinks although in turtle this does not really matter total triples m updated october   data format ntriples rdf license cc  mb gzip mb uncompressed download the rdf data is serialized using the ntriples format encoded as utf text and compressed with gzip rdf httprdffreebasecomnsmj httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmnrg httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmjgd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmd httpwwwworgowlsameas httpwwwwikidataorgentityq  httprdffreebasecomnsmgd httpwwwworgowlsameas httpwwwwikidataorgentityq  license freebase data dumps are provided free of charge for any purpose with regular updates by google they are distributed like freebase itself under the creative commons attribution aka ccby and use is subject to the terms of service the freebasewikidata id mappings are provided under cc and can be used without restrictions citing if youd like to cite these data dumps in a publication you may use google freebase data dumps httpsdevelopersgooglecomfreebasedata month day year or as bibtex bibtex misc except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel market report sunovion pharmaceuticals inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing sunovion pharmaceuticals inc  product pipeline review   feb    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents request details related global markets directs sunovion pharmaceuticals inc  product pipeline review   provides an overview of the sunovion pharmaceuticals incs pharmaceutical research and development focusthe report provides comprehensive information on the therapeutics under development by sunovion pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basisthe report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantagenote certain sections in the report may be removed or altered based on the availability and relevance of datareport scopethe report provides a snapshot of the pipeline therapeutic landscape of sunovion pharmaceuticals incthe report provides overview of sunovion pharmaceuticals inc including its business description key facts and locations and subsidiariesthe report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activitiesthe report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stagesthe report assesses sunovion pharmaceuticals incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule typethe report features sunovion pharmaceuticals incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projectsreasons to get this reportevaluate sunovion pharmaceuticals incs strategic position with total access to detailed information on its product pipelinegain strategically significant competitor information analysis and insights to formulate effective rd strategiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageidentify and understand important and diverse types of therapeutics under development for sunovion pharmaceuticals incidentify potential new clients or partners in the target demographicplan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeuticsdevise corrective measures for pipeline projects by understanding sunovion pharmaceuticals incs pipeline depth and focus of pipeline therapeuticsdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contentstable of contents list of tables list of figures sunovion pharmaceuticals inc snapshot sunovion pharmaceuticals inc overview key information key facts sunovion pharmaceuticals inc  research and development overview key therapeutic areas sunovion pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities sunovion pharmaceuticals inc  pipeline products glance sunovion pharmaceuticals inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities sunovion pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities sunovion pharmaceuticals inc  early stage pipeline products indcta filed productscombination treatment modalities preclinical productscombination treatment modalities discovery productscombination treatment modalities sunovion pharmaceuticals inc  drug profiles eslicarbazepine acetate product description mechanism of action rd progress dasotraline product description mechanism of action rd progress glycopyrrolate product description mechanism of action rd progress dsp product description mechanism of action rd progress dsp product description mechanism of action rd progress sep product description mechanism of action rd progress sep product description mechanism of action rd progress sep product description mechanism of action rd progress small molecule  for neuropsychiatric disorders product description mechanism of action rd progress small molecule for neuropsychiatric disorders product description mechanism of action rd progress small molecule to inhibit damino acid oxidase for neuropathic pain inflammatory pain and memory impairment product description mechanism of action rd progress ep product description mechanism of action rd progress small molecules for central nervous system disorders product description mechanism of action rd progress small molecules to modulate gpcr and ion channel for psychiatric disorders product description mechanism of action rd progress sunovion pharmaceuticals inc  pipeline analysis sunovion pharmaceuticals inc  pipeline products by target sunovion pharmaceuticals inc  pipeline products by route of administration sunovion pharmaceuticals inc  pipeline products by molecule type sunovion pharmaceuticals inc  pipeline products by mechanism of action sunovion pharmaceuticals inc  recent pipeline updates sunovion pharmaceuticals inc  dormant projects sunovion pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles dasotraline dsp dsp sep tecastemizole sunovion pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablessunovion pharmaceuticals inc key information sunovion pharmaceuticals inc key facts sunovion pharmaceuticals inc  pipeline by indication  sunovion pharmaceuticals inc  pipeline by stage of development  sunovion pharmaceuticals inc  monotherapy products in pipeline  sunovion pharmaceuticals inc  partnered products in pipeline  sunovion pharmaceuticals inc  partnered products combination treatment modalities  sunovion pharmaceuticals inc  preregistration  sunovion pharmaceuticals inc  phase iii  sunovion pharmaceuticals inc  phase ii  sunovion pharmaceuticals inc  phase i  sunovion pharmaceuticals inc  indcta filed  sunovion pharmaceuticals inc  preclinical  sunovion pharmaceuticals inc  discovery  sunovion pharmaceuticals inc  pipeline by target  sunovion pharmaceuticals inc  pipeline by route of administration  sunovion pharmaceuticals inc  pipeline by molecule type  sunovion pharmaceuticals inc  pipeline products by mechanism of action  sunovion pharmaceuticals inc  recent pipeline updates  sunovion pharmaceuticals inc  dormant developmental projects sunovion pharmaceuticals inc  discontinued pipeline products  sunovion pharmaceuticals inc other locations sunovion pharmaceuticals inc subsidiaries list of figuressunovion pharmaceuticals inc  pipeline by top  indication  sunovion pharmaceuticals inc  pipeline by stage of development  sunovion pharmaceuticals inc  monotherapy products in pipeline  sunovion pharmaceuticals inc  partnered products in pipeline  sunovion pharmaceuticals inc  pipeline by top  target  sunovion pharmaceuticals inc  pipeline by route of administration  sunovion pharmaceuticals inc  pipeline by molecule type  sunovion pharmaceuticals inc  pipeline products by top  mechanism of action   this report does not have a list of companies mentioned available this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc sunovion sunovion  twitter skip to content home home home current page moments moments moments current page search query search twitter saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어    have an account log in have an account remember me · forgot password new to twitter sign up sunovionverified account sunovion tweets tweets current page  following following  followers followers k likes likes    more likes unmute sunovion mute sunovion follow following unfollow blocked unblock pending cancel sunovionverified account sunovion focused on the innovative application of science and medicine to help people with serious medical conditions global sunovioncom joined november   photos and videos photos and videos tweets tweets tweets current page tweets  replies media you blocked sunovion are you sure you want to view these tweets viewing tweets wont unblock sunovion yes view profile close sunovion followed sunovion‏verified account sunovion h hours ago more copy link to tweet embed tweet we hope youll join the copdfoundation as we celebrate the life accomplishments and continued legacy of their founder john w walsh  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion h hours ago more copy link to tweet embed tweet theres no right or wrong way to feel about epilepsy your feelings might change from month to month or moment to moment supportpictwittercomrmhrlgab  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion h hours ago more copy link to tweet embed tweet factfriday mentalhealth conditions are a top cause of workplace disability these tips may be helpful at work httpbddymehgsqd pictwittercomejpifqb  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion h hours ago more copy link to tweet embed tweet nobuhiko tamura sunovions chairman and ceo throws out the ceremonial first pitch at fenway park on july httpbddymehyynj   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion h hours ago more copy link to tweet embed tweet join the copdfoundation in honoring the life and accomplishments of john w walsh their founder and a true copd advocacy pioneer  replies  retweets  likes reply retweet retweeted like liked thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet having epilepsy is more than just having seizures – it can affect every part of your life physical mental and emotionalpictwittercomcpdikktxw  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion retweeted tim garvin‏ timgarvinuw jul  more copy link to tweet embed tweet bravo sunovion and the redsox for partnering to strengthen community and improve lives redsoxfund unitedwayofcm  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet foods to avoid when you have copd soda veggies that cause bloating dairy products if mucus is an issue and high sodium foodspictwittercomjfgmpwtu  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet september nd is the first day of the autumn escape bike trek learn more at httpwwwsunbiketrekcom pictwittercommhmvyjg  replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet watch and listen to how excited sunovion employees were at sunoviondayfenway on july thhttpsyoutubeakbpeounto   replies  retweets  like reply retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet check out epilepsyfdn to learn how to take action and manage epilepsy and seizures httpbddymeeijznu pictwittercommftumkivp  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet talking about mentalhealth can be sensitive view this tip sheet for best practices  to help reframe mental health httpbddymeegnxw pictwittercomijdnsciww  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet check out epilepsyfdn’s httptalkaboutitorg  to learn how you can start a conversation about epilepsy with otherspictwittercommyorzbsn  reply  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet factfriday  in  people experience a mentalhealth condition in any given yearpictwittercomoxdtqcca  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion retweeted greg grunberg‏verified account greggrunberg jul  more copy link to tweet embed tweet come check our panel superstars in childrens fiction rm abc from pmpictwittercomlnarhdhvi  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion retweeted talkaboutitorg‏ talkaboutitorg jul  more copy link to tweet embed tweet greggrunberg is at sdcc superstars in childrens fiction panel  pm pt dreamjumper talkaboutit epilepsyawareness  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet planning a vacation if you have copd choose a climate without extreme temperatures and low humidity or a beach locale thats not too hotpictwittercomqodwpdrprk  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet sunovion receives health canada approval to treat adolescents with schizophrenia read the full press release here httpbitlyuhsdke pictwittercompmsdarqcos  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet tbt to the afspnational overnight walk last month sunovion employees walked to raise awareness for suicide preventionpictwittercomralyinhs  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion‏verified account sunovion jul  more copy link to tweet embed tweet shane an employee in the ma office talks about the future of sunovion and the upcoming career opportunitieshttpbddymegntyni   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo sunovion hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info sunovion  wikipedia sunovion from wikipedia the free encyclopedia jump to navigation search sunovion pharmaceuticals inc type subsidiary industry pharmaceuticals founded  headquarters marlborough massachusetts united states key people nobuhiko tamura chairman and ceo products latuda aptiom brovana lunesta xopenex omnaris alvesco zetonna parent dainippon sumitomo pharma website httpwwwsunovioncom sunovion pharmaceuticals inc former nasdaq sepr known until october   as sepracor inc prior to its acquisition by dainippon sumitomo pharma of japan is a pharmaceutical company founded in  by timothy j barberich steve matson and bob bratzler it was originally located in princeton new jersey and then relocated to marlborough massachusetts in addition to its headquarters location in marlborough massachusetts sunovion has locations in london england mississauga ontario canada and fort lee new jersey contents  company history  acquisition by dainippon sumitomo  beneficiaries partners and subsidiaries  eslicarbazepine acetate  omnaris and alvesco  references  external links company historyedit the companys initial focus was on the development of single isomers and active metabolites this concept allowed barberich and doug reedich to generate a patent estate that served the company well for many years therapeutically sepracors products were focused on the treatment of central nervous system and respiratory disorders under the direction of gunnar aberg and john mccullough the primary source of its revenue was the approximately  million annually from its xopenex franchise of drugs launched under the marketing leadership of john simon with the direct involvement of medical communications under dean handley it is available as a multidose inhaler mdi or nebulized udv form the insomnia drug lunesta eszopiclone was discovered by tom jerussi approved by the us food and drug administration fda in december  and launched in april  under the marketing leadership of tim healy on february   sepracor filed a new drug application for brovana patented by gunnar aberg and john morley also launched under john simon to treat chronic obstructive pulmonary disease all of the launch drugs were manufactured under the leadership of walter piskorskicitation needed in september  the company announced it would acquire cynapsus therapeutics for approximately  million specifically expanding sunovians central nervous system drug portfolio through the deal sunovion would acquire cynapsus’ phase iii parkinson’s disease candidate drug apl acquisition by dainippon sumitomoedit on september   shares of sepracor were halted on the nasdaq due to pending news of a takeover bid by japanese drugmaker dainippon sumitomo according to the associated press dainippon planned to offer  billion for sepracor a nearly  premium over the stocks closing price on september  aside from acquiring such drugs as lunesta and xopenex analysts said the acquisition would give dainippon access to sepracors sales force of roughly  which would open an avenue for the japanese company to market its drugs in the united states sepracor was set to face stiff generic competition from its expiring patents xopenex in  and lunesta in  and had failed to discover any viable drugs in nearly  years a formal announcement of the acquisition was made on october   which stated that sunovion would be an indirect wholly owned subsidiary of dainippon sumitomo pharma co ltd beneficiaries partners and subsidiariesedit eslicarbazepine acetateedit in  bial agreed with sepracor that its antiepileptic eslicarbazepine acetate trade name aptiom would be produced in sepracors facilities and supervised by bial omnaris and alvescoedit the company acquired omnaris and alvesco for m upfront and an addition m in potential milestones alvesco revenues for q were  million because returns from the stocking in q exceeded the demand in q the company disclosed a  forecast of –m for omnaris and –m for alvesco yielding a combined total of mm in year  of a launch however revenues continue to be dismal prompting criticisms and concerns over the purchase price relative to minuscule income referencesedit  a b company press release  sepr profile for sepracor inc  yahoo finance  sunovion to acquire cynapsus for m  gen news highlights  gen   httpsfinanceyahoocomnewsdainipponofjapanacquiresapfhtmlxsectopstoriesposassetccode  tse suspends trade in dainippon sumitomo pharma  september  – via reuters   drugmaker sepracor accepts b buyout offer from japans dainippon  xconomy  september    aol finance news  latest business headlines from aol   bial  caring for your health  external linksedit sunovion pharmaceuticals inc retrieved from httpsenwikipediaorgwindexphptitlesunovionoldid categories companies formerly listed on nasdaqbiotechnology companies of the united statescompanies based in middlesex county massachusettsmarlborough massachusettscompanies established in hidden categories all articles with unsourced statementsarticles with unsourced statements from may  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages français edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view sunovion pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports sunovion pharmaceuticals inc  product pipeline review  sunovion pharmaceuticals inc  product pipeline review   wgr  april  global  pages global markets direct description table of content sample report enquiry before buy related reports sunovion pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘sunovion pharmaceuticals inc  product pipeline review  ’ provides an overview of the sunovion pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of sunovion pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of sunovion pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of sunovion pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the sunovion pharmaceuticals inc’s pipeline productsreasons to buy evaluate sunovion pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of sunovion pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the sunovion pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of sunovion pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of sunovion pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of sunovion pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures sunovion pharmaceuticals inc snapshot sunovion pharmaceuticals inc overview key information key facts sunovion pharmaceuticals inc  research and development overview key therapeutic areas sunovion pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities sunovion pharmaceuticals inc  pipeline products glance sunovion pharmaceuticals inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities sunovion pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities sunovion pharmaceuticals inc  early stage pipeline products indcta filed productscombination treatment modalities preclinical productscombination treatment modalities discovery productscombination treatment modalities sunovion pharmaceuticals inc  drug profiles eslicarbazepine acetate product description mechanism of action rd progress dasotraline product description mechanism of action rd progress glycopyrrolate product description mechanism of action rd progress dsp product description mechanism of action rd progress dsp product description mechanism of action rd progress sep product description mechanism of action rd progress sep product description mechanism of action rd progress small molecule  for neuropsychiatric disorders product description mechanism of action rd progress small molecule for neuropsychiatric disorders product description mechanism of action rd progress small molecule to inhibit damino acid oxidase for neuropathic pain inflammatory pain and memory impairment product description mechanism of action rd progress ep product description mechanism of action rd progress small molecules for central nervous system disorders product description mechanism of action rd progress sunovion pharmaceuticals inc  pipeline analysis sunovion pharmaceuticals inc  pipeline products by target sunovion pharmaceuticals inc  pipeline products by route of administration sunovion pharmaceuticals inc  pipeline products by molecule type sunovion pharmaceuticals inc  pipeline products by mechanism of action sunovion pharmaceuticals inc  recent pipeline updates sunovion pharmaceuticals inc  dormant projects sunovion pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles dasotraline dsp dsp sep tecastemizole sunovion pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablessunovion pharmaceuticals inc key information sunovion pharmaceuticals inc key facts sunovion pharmaceuticals inc  pipeline by indication  sunovion pharmaceuticals inc  pipeline by stage of development  sunovion pharmaceuticals inc  monotherapy products in pipeline  sunovion pharmaceuticals inc  partnered products in pipeline  sunovion pharmaceuticals inc  partnered products combination treatment modalities  sunovion pharmaceuticals inc  preregistration  sunovion pharmaceuticals inc  phase iii  sunovion pharmaceuticals inc  phase ii  sunovion pharmaceuticals inc  phase i  sunovion pharmaceuticals inc  indcta filed  sunovion pharmaceuticals inc  preclinical  sunovion pharmaceuticals inc  discovery  sunovion pharmaceuticals inc  pipeline by target  sunovion pharmaceuticals inc  pipeline by route of administration  sunovion pharmaceuticals inc  pipeline by molecule type  sunovion pharmaceuticals inc  pipeline products by mechanism of action  sunovion pharmaceuticals inc  recent pipeline updates  sunovion pharmaceuticals inc  dormant developmental projects sunovion pharmaceuticals inc  discontinued pipeline products  sunovion pharmaceuticals inc other locations sunovion pharmaceuticals inc subsidiaries list of figuressunovion pharmaceuticals inc  pipeline by top  indication  sunovion pharmaceuticals inc  pipeline by stage of development  sunovion pharmaceuticals inc  monotherapy products in pipeline  sunovion pharmaceuticals inc  partnered products in pipeline  sunovion pharmaceuticals inc  pipeline by top  target  sunovion pharmaceuticals inc  pipeline by top  route of administration  sunovion pharmaceuticals inc  pipeline by top  molecule type  sunovion pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send sunovion pharmaceuticals inc  product pipeline review    rnr market research advanced search     salesrnrmarketresearchcom search market research reports ﻿ market research assistance salesrnrmarketresearchcom on the web related markets biotechnologybiomaterialsbiomarkersstem celldrug discoveryindustrial biotechnologywound careenzymemicroarraybiopharmaceuticalcell culture related market reportssunovion pharmaceuticals inc  product pipeline review  sunovion pharmaceuticals inc  product pipeline review   home  life sciences  pharmaceuticals  report detail sunovion pharmaceuticals inc  product pipeline review   publisher name  global markets direct date feb no of pages  price single user license us  corporate user license us  report descriptiontable of contentnews  blogother reportsour offerings global markets directs sunovion pharmaceuticals inc  product pipeline review   provides an overview of the sunovion pharmaceuticals incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by sunovion pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of sunovion pharmaceuticals inc the report provides overview of sunovion pharmaceuticals inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses sunovion pharmaceuticals incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features sunovion pharmaceuticals incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate sunovion pharmaceuticals incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for sunovion pharmaceuticals inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding sunovion pharmaceuticals incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope sunovion pharmaceuticals inc  product pipeline review   table of contents table of contents  list of tables  list of figures  sunovion pharmaceuticals inc snapshot  sunovion pharmaceuticals inc overview  key information  key facts  sunovion pharmaceuticals inc  research and development overview  key therapeutic areas  sunovion pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  sunovion pharmaceuticals inc  pipeline products glance  sunovion pharmaceuticals inc  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  sunovion pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  sunovion pharmaceuticals inc  early stage pipeline products  indcta filed productscombination treatment modalities  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  sunovion pharmaceuticals inc  drug profiles  eslicarbazepine acetate  product description  mechanism of action  rd progress  dasotraline  product description  mechanism of action  rd progress  glycopyrrolate  product description  mechanism of action  rd progress  dsp  product description  mechanism of action  rd progress  dsp  product description  mechanism of action  rd progress  sep  product description  mechanism of action  rd progress  sep  product description  mechanism of action  rd progress  sep  product description  mechanism of action  rd progress  small molecule  for neuropsychiatric disorders  product description  mechanism of action  rd progress  small molecule for neuropsychiatric disorders  product description  mechanism of action  rd progress  small molecule to inhibit damino acid oxidase for neuropathic pain inflammatory pain and memory impairment  product description  mechanism of action  rd progress  ep  product description  mechanism of action  rd progress  small molecules for central nervous system disorders  product description  mechanism of action  rd progress  small molecules to modulate gpcr and ion channel for psychiatric disorders  product description  mechanism of action  rd progress  sunovion pharmaceuticals inc  pipeline analysis  sunovion pharmaceuticals inc  pipeline products by target  sunovion pharmaceuticals inc  pipeline products by route of administration  sunovion pharmaceuticals inc  pipeline products by molecule type  sunovion pharmaceuticals inc  pipeline products by mechanism of action  sunovion pharmaceuticals inc  recent pipeline updates  sunovion pharmaceuticals inc  dormant projects  sunovion pharmaceuticals inc  discontinued pipeline products  discontinued pipeline product profiles  dasotraline  dsp  dsp  sep  tecastemizole  sunovion pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables sunovion pharmaceuticals inc key information  sunovion pharmaceuticals inc key facts  sunovion pharmaceuticals inc  pipeline by indication   sunovion pharmaceuticals inc  pipeline by stage of development   sunovion pharmaceuticals inc  monotherapy products in pipeline   sunovion pharmaceuticals inc  partnered products in pipeline   sunovion pharmaceuticals inc  partnered products combination treatment modalities   sunovion pharmaceuticals inc  preregistration   sunovion pharmaceuticals inc  phase iii   sunovion pharmaceuticals inc  phase ii   sunovion pharmaceuticals inc  phase i   sunovion pharmaceuticals inc  indcta filed   sunovion pharmaceuticals inc  preclinical   sunovion pharmaceuticals inc  discovery   sunovion pharmaceuticals inc  pipeline by target   sunovion pharmaceuticals inc  pipeline by route of administration   sunovion pharmaceuticals inc  pipeline by molecule type   sunovion pharmaceuticals inc  pipeline products by mechanism of action   sunovion pharmaceuticals inc  recent pipeline updates   sunovion pharmaceuticals inc  dormant developmental projects  sunovion pharmaceuticals inc  discontinued pipeline products   sunovion pharmaceuticals inc other locations  sunovion pharmaceuticals inc subsidiaries  list of figures sunovion pharmaceuticals inc  pipeline by top  indication   sunovion pharmaceuticals inc  pipeline by stage of development   sunovion pharmaceuticals inc  monotherapy products in pipeline   sunovion pharmaceuticals inc  partnered products in pipeline   sunovion pharmaceuticals inc  pipeline by top  target   sunovion pharmaceuticals inc  pipeline by route of administration   sunovion pharmaceuticals inc  pipeline by molecule type   sunovion pharmaceuticals inc  pipeline products by top  mechanism of action   renewable energy sources needs to boost global microgrids marketthe global market for microgrid was worth us billion in  and is anticipated to touch an estimate of us billion by  dealers in the market for microgrids are incessantly improving the network hostinghellipmanufacturing trends in the coming daysthe manufacturing industry may be encountering some breezes but it is irrefutably in the middle of a technological revival that is altering the appearance structures and practices of the modern factory notwithstanding the jeopardies andhelliptop  emerging technologiesthe world economic forum wef and scientific american lately unveiled the major technological innovation list of the top ten emerging technologies this list emphasizes on the technological developments which have the supremacy to transform industrieshellipglobal biosimilars market to be led by novartis by biologics which are typically inoculated or injected are formed in living entities making them more challenging and costly to manufacture than the usual pills contrived from chemicals observing that mockups are mostly identical to thehellipglobal thyroid gland disorder treatment market to grow steadilythe global thyroid gland disorder treatment market was worth us billion in  and is projected to reach a market value of us billion in  intensifying at a cagr of  from  to   thehellip highspeed data transmission and high volume needs propel fiber optic connectors market fiber optic connectors are a substantial fragment of the global telecommunication industry optical fibers are joined using fiber optic connectors which allow the light conduction between two consecutive optical fibers an additional im…extensive use of digital technologies for diagnostic applications to boost global optical imaging market the global optical imaging system market is predicted to reach us  billion by  it is expected to grow at a stable rate and will post a cagr of more than  in the coming years the growing market infiltration of digital …foremost trends in global pet care market the global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments it is estimated that the global pet care market will grow at a cagr o…china to review its food security laws china has arisen as the globe’s firmest developing economy in addition china brags about the biggest population pool in the world in recent times the one child policy in the republic was terminated this is anticipated to upsur…improving standards of living to boost global consumer durables market consumer durables is a cataloguing of consumer goods that are not essential to be bought very often as they are fashioned in a way so as to last for an extended period of time profits in the consumer durables sector were most profoundly… global and europe bacillus subtilis market  analysis and outlook to  published jul        price us  onwards        pages  this report presents a comprehensive overview of the bacillus subtilis market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics structure characteristics main players growth and demand drivers etc as a detailed analysis report it covers all details inside analysis and opinion in bacillus subtilis industry this report focus global and eu asiapacific methoxypsoralen  market report  published jul        price us  onwards        pages  in this report the asiapacific methoxypsoralen  market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split asiapacific into several key regions with sales k mt revenue million usd market share and growth rate of methoxypsoralen  for these regions from  to  forecast including  china  japan  global dental cements market professional survey report  published jul        price us  onwards        pages  this report studies dental cements in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  this report focuses on top manufacturers in global market with production price revenue and market share for each manufacturer covering  m  kerr dental  shofu  ceramir crown  bridge  dentsply  top  physiological saline manufacturers in north america europe asiapacific south america middle east and africa published jul        price us  onwards        pages  this report will be delivered in  business days after the order is placed the global physiological saline market size will be xx million usd in  from the xx million usd in  with a cagr compound annual growth rate xx from  to  this report studies physiological saline in global market especially in north america europe asiapacific south america middle east and africa focuses on the top  physiological saline play asiapacific coagulation reagent market report  published jul        price us  onwards        pages  in this report the asiapacific coagulation reagent market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split asiapacific into several key regions with sales k pcs revenue million usd market share and growth rate of coagulation reagent for these regions from  to  forecast including  china  japan  south korea  china physiological saline market report status and outlook published jul        price us  onwards        pages  this report will be delivered in  business days after the order is placed the physiological saline market size will be xx million usd in  in china from the xx million usd in  with a cagr compound annual growth rate xx from  to  in china market the top players include  baxter  hospira pfizer  fresenius kabi  bbraun  otsuka  kelun group  cr doublecran   asiapacific budesonide bud market report  published jul        price us  onwards        pages  in this report the asiapacific budesonide bud market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split asiapacific into several key regions with sales k units revenue million usd market share and growth rate of budesonide bud for these regions from  to  forecast including  china  japan  south korea  overactive bladder treatment market by pharmacotherapy anticholinergic solifenacin oxybutynin fesoterodine darifenacin mirabegron botox neurostimulation disease type idiopathic and neurogenic bladder overactivity  global forecast to  published jul        price us  onwards        pages  “global overactive bladder treatment market is projected to grow at a cagr of ” the global overactive bladder treatment market is estimated to grow at a cagr of  from  to  to reach usd  billion by  the key factors driving the growth of this market include the rising prevalence of overactive bladder oab coupled with the growing geriatric population and rising neurological disorders namely parkinson’s disease pd stroke asiapacific cardiovascular and soft tissue repair patches market report  published jul        price us  onwards        pages  in this report the asiapacific cardiovascular and soft tissue repair patches market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split asiapacific into several key regions with sales k units revenue million usd market share and growth rate of cardiovascular and soft tissue repair patches for these regions from  to  forecast including services value for money we believe in optimum utilization of available budget and resources while servicing our clients your market research requirements we keep the same approach in focus to help you get the best value for your s ever growing inventory ranging from the smallest feasible  required data datasheets data facts swot analysis company profiles etc to full research reports that help you make decisions our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than  niche sectors one stop solution need a custom research report on medical devices market require all available business intelligence on d printing industry exploring fb sector of a particular countryregion rnrmarketresearchcom is your onestopsolution to all market intelligence needs we not only offer custom research and consulting services we also bundle reports to meet your needs and help you fetch the data analysis you require for your business dedicated client engagement not limited to only finding relevant reports for you our client engagement team dedicates its efforts to understand your business need and accordingly maps available research data to help you move forward call your client engagement executive any time of your day and get your questions answered in order to make the correct business decision saving time and efforts simply share your research requirement details with us and let us do all the hard work to find required intelligence for you when you add up our one stop solution and dedicated client engagement services mentioned above you obviously know the time and effort saving you do by working with us payment flexibility working with fortune  organizations we understand the importance of being flexible for payments share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done postpurchase research support have questions after reading a report  datasheet bought through us not sure about the methodology used for data available in the research talk to us  share your questions with us and if required we will connect you with the analystsauthors of the reports and ensure you get satisfactory answers for the same need more data  analysis  reports on the topic of your researchproject the rnrmarketresearchcom team is here for you x to support you with your postpurchase requirements subscription offers  packages get in touch with us for more details  salesrnrmarketresearchcom       ad hoc pay  as  you  go  bucket subscriptions fixed cost for of reports customize  personalize as per your needs avail upto  discount on below publisher reports azoth analytics technavio sunovion  sunovion – hands on event page sunovion close video hands on  marked the fifth year of sunovion’s annual community service program hands on since the inception of the program in  sunovion employees have volunteered more than  hours to support youth organizations and community service efforts around our headquarters located in marlborough massachusetts and its office in fort lee new jersey sunovion will continue to expand hands on through employee volunteer efforts on projects throughout the us as well as in communities where we have offices in the uk and canada event highlights  employees participated in hands on in  more than k community service hours since   community projects supported in  in our own words responsibility our employees have a collective commitment to give back make a difference together and improve lives learn more about how we care for the community community building building stronger communities where our employees live and work discover how we support our communities who we are sunovions vision is to lead the way to a healthier world learn more about us pharmaceuticals market research reports on market size and competitive analysis advanced search     salesrnrmarketresearchcom search market research reports market research assistance salesrnrmarketresearchcomon the web refine resultby datelast monthlast  monthslast  monthslast yearlast  years by price  home     life sciences    pharmaceuticals pharmaceuticals market research reports the global pharmaceutical market has persistently experienced significant growth due to the everincreasing demand for novel and more effective drugs the reasons for this steady increase in the demand for drugs worldwide can be attributed to population growth newer and more complex disease conditions ageing population and the increased prevalence of chronic and infectious diseases some of which still remain incurable and fatal such numerous unmet needs and high demand rates have triggered the boost in rd investments by key industry sectors greatly driving the growth of this industry the pharmaceutical market valued as a multibillion dollar market is undoubtedly the largest revenue generator for the life sciences industry the pharmaceutical industry can be divided into numerous market segments based on the different therapeutic areas and applications the largest segment the market for cardiovascular drugs records huge sales every year the rising world population rapview more the global pharmaceutical market has persistently experienced significant growth due to the everincreasing demand for novel and more effective drugs the reasons for this steady increase in the demand for drugs worldwide can be attributed to population growth newer and more complex disease conditions ageing population and the increased prevalence of chronic and infectious diseases some of which still remain incurable and fatal such numerous unmet needs and high demand rates have triggered the boost in rd investments by key industry sectors greatly driving the growth of this industry the pharmaceutical market valued as a multibillion dollar market is undoubtedly the largest revenue generator for the life sciences industry the pharmaceutical industry can be divided into numerous market segments based on the different therapeutic areas and applications the largest segment the market for cardiovascular drugs records huge sales every year the rising world population rapid ageing of the same and an increased prevalence of diseases are the major factors driving growth of this industry the recent breakthroughs in proteomics and genomics have led to the development of modernized approaches to drug discovery and development in the industry for the possibility of newer advanced and more sophisticated therapies and drugs developments in biotechnology research have led to introduction of advanced therapies involving biopharmaceuticals regenerative medicine stem cells etc these new age therapies and products have caused ease of treatment procedures and enabled speedy recovery from various disorders technological growth in such interdisciplinary fields has opened up new arenas in drug discovery drug delivery and life sciences researchview less therapeuticsdiseases  treatmentclinical trialdietary supplementsbiopharmaceuticalspharmaceutical packagingpain managementpandemic vaccinebiosimilarpharmaceutical distributionover the counter otc druganesthesia drugscancer vaccinepharmaceutical technologyradiopharmaceuticalprescription drugspharmaceutical detailingclinical nutrition pharmaceuticals market research reports titlepublishedprice  global and japan hypolipidemic drugs market analysis reportby qyresearch group e xx million usd in  with a cagr of xx this report studies the hypolipidemic drugs development status and future trend in japan focuses on top players in japan also splits hypolipidemic drugs by type and by applications to fjul global and europe bacillus subtilis market  analysis and outlook to by qyresearch group players growth and demand drivers etc as a detailed analysis report it covers all details inside analysis and opinion in bacillus subtilis industry this report focus global and europe market it covers details players regions prjul global and europe antipsychotic drugs market  analysis and outlook to by qyresearch group rs growth and demand drivers etc as a detailed analysis report it covers all details inside analysis and opinion in antipsychotic drugs industry this report focus global and europe market it covers details players regions product type anjul asiapacific vitamin  mineral supplement market by manufacturers regions type and application forecast to by global info research mins are stored in the bodys cells and do not pass out of the body as easily as watersoluble vitamins do fatsoluble vitamins include vitamins a d e and k minerals these include calcium copper iron magnesium phosphorus potassium jul asiapacific pressure ulcer treatment products market by manufacturers regions type and application forecast to by global info research sore pressure ulcer commonly occur on the elbows back of the head buttocks heels shoulders hips ankles and back scope of the report this report focuses on the pressure ulcer treatment products in asiapacific market jul asiapacific narcolepsy drug market by manufacturers regions type and application forecast to by global info research of muscle strength known as cataplexy these spells can be brought on by strong emotions less commonly there may be inability to move or vivid hallucinations while falling asleep or waking up people with narcolepsy tend to sleep about the same nujul asiapacific maca extract market by manufacturers regions type and application forecast to by global info research sed in many of the best male enhancement pills maca root extract is contained in many leading male enhancement supplements and is widely used to treat hot flushes memory loss stress depression and fertility scope of the reportjul asiapacific lipoic acid market by manufacturers regions type and application forecast to by global info research into a lipoic acid alpha lipoic acid r lipoic acid and s lipoic acid common commercially available lipoic acid are alpha lipoic acid so in the report the volume of lipoic acid is calculated by alpha lipoic acid scope of the jul global antipsychotic drugs detailed analysis report by qyresearch group regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in antipsychotic drugs industry this report focus global market it covers djul global sodium hyaluronate market professional survey report by qyresearch group turers in global market with production price revenue and market share for each manufacturer covering  contipro  lifecore biomedical  seikagaku corporation  vsy biotechnology  fidia farmaceutici spajul                 next » avail upto  discount on below publisher reports azoth analytics technavio